Actively Recruiting

Age: 1Year - 21Years
All Genders
NCT06574698

Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

Led by Guangzhou Women and Children's Medical Center · Updated on 2024-08-28

64

Participants Needed

1

Research Sites

451 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To explore the efficacy of adding anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy for newly diagnosed high risk neuroblastoma patients. To investigate wether anding Naxitamab in the induction phase will improve the response rate at the end of induction therapy and further improve the overall survival rate.

CONDITIONS

Official Title

Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

Who Can Participate

Age: 1Year - 21Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Children with newly diagnosed stage 4 neuroblastoma aged over 18 months regardless of biology
  • Children aged 12-18 months with stage 4 neuroblastoma and unfavorable biology (MYCN amplification, poor histopathology, or DNA index = 1)
  • Children with MYCN amplification regardless of age or biology in stage 4
  • Children with stage 3 neuroblastoma with MYCN amplification or over 18 months with poor histopathology
  • Children with stage 2A/2B neuroblastoma with MYCN amplification
  • Patients must be aged 12 months or older and 21 years or younger at diagnosis
Not Eligible

You will not qualify if you...

  • Infants younger than 1 year old
  • Children aged 12-18 months with stage 4 neuroblastoma but favorable biology
  • Stage 3 neuroblastoma patients with favorable biology
  • Patients who received immunosuppressive treatment (excluding local steroids) within 4 weeks before enrollment
  • Patients currently receiving any investigational drug
  • Patients with medical conditions interfering with study participation or results, including malabsorption syndrome, mental illness, substance abuse
  • Patients with significant unrelated serious medical conditions that may interfere with treatment or increase toxicity

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Guangzhou Women And Children's Medical Center

Guanzhou, Guangdong, China, 510000

Actively Recruiting

Loading map...

Research Team

W

Wenyue Si, Bachelor

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here